Aducanumab: On the verge of making history in Alzheimer’s disease
When Biogen and Eisai terminated aducanumab’s Phase III program in early Alzheimer’s disease (AD) for futility in March 2019, a mere two months... In DRG Blog/ August, 2020 Four NMEs Hope to Keep Up Momentum in the U.S. Migraine Market
For these new entrants, differentiation is evident but access is critical - and each faces market headwinds. 2018 marked a turning point in the U.S... In DRG Blog/ April, 2020 Ophthalmology on a Roll: Key U.S. Market Events in May 2019
New product launches, product acquisitions, and life-cycle management strategies for existing products (e.g., expansion into related indication)... In DRG Blog/ May, 2019 Eylea and the Diabetic Macular Edema Market: What Lies Ahead?
Diabetic macular edema (DME) occurs in patients with diabetes as a consequence of diabetic retinopathy and is typically referred to as the leading... In DRG Blog/ December, 2018 What Are the Opportunities and Challenges to Drug Development for Diabetic Retinopathy?
Diabetic retinopathy (DR) occurs as a consequence of diabetes and is the leading cause of visual impairment and blindness among the working-age... In DRG Blog/ December, 2018